



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ





شبكة المعلومات الجامعية



شبكة المعلومات الجامعية

التوثيق الالكتروني والميكرو فيلم





شبكة المعلومات الجامعية

# جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
على هذه الأفلام قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15 – 20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of  
15 – 25c and relative humidity 20-40 %



شبكة المعلومات الجامعية



بالرسالة صفحات

لم ترد بالأصل





شبكة المعلومات الجامعية



# بعض الوثائق الأصلية تالفة

**PHOSPHODIAESTRASE INHIBITORS  
VERSUS CATECHOLAMINES A COMPARATIVE  
HEMODYNAMIC STUDY IN PATIENTS  
WITH CIRCULATORY FAILURE**

*Thesis  
Submitted in Partial fulfilment  
of the MD Degree in  
Critical care medicine*

*By  
Ashraf Mohe Al-Deen Nadim*

**Supervisors**

**Prof. Dr Sherif Moktar**  
**Director of critical care Medicine**  
**Cairo university hospital**

**Prof. Dr Hossam Mowafi**  
**Chief of critical Care Medicine**  
**Cairo university**

**Dr. Faheem Ragab M.D**  
**Assistant Prof. of Critical Care Medicine**  
**Cairo university**

**Faculty of Medicine**  
**Cairo University**  
**2001**

B  
0072

مختصر

اجتماع لجنة الحكم على الرسائل العلمية

الاجتماع / ١٩٨٠ / ١٠ / ١٠

تولت الرسالة على درجة الماجستير / الدكتور

في الطب العام

phosphocholates inhibits release  
Calculation of the circulatory future  
Calculation of the circulatory future

الاجتماع / ١٩٨٠ / ١٠ / ١٠  
الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠  
الاجتماع / ١٩٨٠ / ١٠ / ١٠

عن المشرفين

متن داخلي

متن خارجي

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

الاجتماع / ١٩٨٠ / ١٠ / ١٠

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ



# Acknowledgement

I would like to express my deep gratitude and high appreciation to my teacher **Prof. Dr Hossam Mowafi**, Professor and chief of critical care medicine department. He was generous in devoting enough time and effort to achieve this work. Needless to say without his constant guidance, cordial help, meticulous supervision and constructive criticism this thesis would not have come to light.

A special acknowledgement to **Prof. Dr. Sherif Moktar**, Professor of cardiology and the God father of Critical care medicine in Egypt. He was the person to put the idea and plane of this work I was fortunate to prepare this thesis under his supervision.

I am specially grateful to **Prof. Dr. Fahim Ragab** for his kind supervision, continuous support and valuable ideas in bringing this work in its present form.

I am especially thankful to all staff members of the critical care department medicine department, third unit who made all the circumstances favorable for me to complete this work especially during the practical part.

Finally but of major importance, was my parents and small family without their love, never fading patience and indispensable support, I would probably not have completed this work.

*Ashraf Mohy*

# Content

<b>Introduction &amp; Aim of Work .....</b>	<b>1</b>
---	----------

## **Review of Literature**

Physiology of the circulatory system .....	4
Pharmacology of inotropic drugs.....	32
Pathophysiology in circulatory failure..-	65
Mechanical Circulatory Support And Other Therapies For Heart Failure .....	92
Monitoring In Critically- Ill Patients .....	102

<b>Patients &amp; Methods .....</b>	<b>132</b>
-------------------------------------	------------

<b>Results .....</b>	<b>146</b>
----------------------	------------

<b>Discussion .....</b>	<b>164</b>
-------------------------	------------

<b>Summary &amp; Conclusion .....</b>	<b>175</b>
---------------------------------------	------------

<b>References .....</b>	<b>180</b>
-------------------------	------------

<b>Arabic summary .....</b>	
-----------------------------	--

# List of Tables

<b>Table (1)</b>	Distribution of systemic blood flow and oxygen consumption in a normal subject at rest in a comfortable environment.
<b>Table (2)</b>	Expected systemic hemodynamic effects of inotropic or ino-vasodilator agents in treatment of heart failure
<b>Table (3)</b>	<i>Showing classification of PDE inhibitors by their chromatography.</i>
<b>Table (4)</b>	<i>Showing half life of enoximone excretion in CHF patients (Okerholm et, al 1987)</i>
<b>Table (5)</b>	Congestive heart failure: proarrhythmic factors (Naccarelli and Godistein, 1989).
<b>Table (6)</b>	<i>List of drug interaction between enoximone and the variety of medications.</i>
<b>Table (7)</b>	<i>Incidences of adverse effects experiences during enoximone administration (Crawford, 1987).</i>
<b>Table (8)</b>	Showing major primary causes of heart failure
<b>Table (9)</b>	Showing Revised NYHA classification
<b>Table (10)</b>	Showing indication and contraindication of mechanical circulatory support.
<b>Table (11)</b>	<i>Mechanical circulatory support- methods (selection)</i>
<b>Table (12)</b>	Monitored physiological variables.
<b>Table (13)</b>	Normal values for the most commonly monitored variables
<b>Table (14)</b>	Showing the relative rating of central venous access technique. <i>(In each category, 1= best, 5= worst).</i>
<b>Table (15)</b>	Showing equipment needed during insertion of Swan-Ganz catheter.
<b>Table (16)</b>	Showing Pressures measurements one-half of anteroposterior chest diastmeter. 1 mm Hg = 133.332 Pascal (Pa)= 0.133 kPa.
<b>Table (17)</b>	Indications for pulmonary artery catheterization
<b>Table (18)</b>	Factors affecting cardiac output <i>(Huge et al., 1994)</i>
<b>Table (19)</b>	Illustrates the relation of the gender in this study.
<b>Table (20)</b>	Range and mean age of the studied group.
<b>Table (21)</b>	Illustrate the percentage of etiology in this study.
<b>Table (22)</b>	Illustrates number and percentage of patients according to NYHA functional class criteria.



<b>Table (23)</b>	Liver functions; range, mean value and standard deviation.
<b>Table (24)</b>	Renal functions; range, mean value and standard deviation.
<b>Table (25)</b>	AF and Rythm disturbance percentage
<b>Table (26)</b>	Showing mean, SD and P.value with maxiumum effects of dobutamine and enoximone on CI (cardiac index)
<b>Table (27)</b>	Showing mean, SD and P.value with maxiumum effects of dobutamine and enoximone on SVI (stroke volume index)
<b>Table (28)</b>	Showing mean, SD and P.value with maxiumum effects of dobutamine and enoximone on SWI (stroke work index)
<b>Table (29)</b>	Showing mean, SD and P.value with maxiumum effects of dobutamine and enoximone on SVRI (systemic vascular resistance)
<b>Table (30)</b>	Showing mean, SD and P.value with maxiumum effects of dobutamine and enoximone on PVRI (pulmonary vascular resistance)
<b>Table (31)</b>	Showing mean, SD and P.value with maxiumum effects of dobutamine and enoximone on PCWP (pulmonary capillary wedge pressure)
<b>Table (32)</b>	Showing mean, SD and P.value with maxiumum effects of dobutamine and enoximone on RAP (right atrial pressure)
<b>Table (33)</b>	Showing mean, SD and P.value with maxiumum effects of dobutamine and enoximone on MAP (mean arterial pressure):
<b>Table (34)</b>	Showing mean, SD and P.value with maxiumum effects of dobutamine and enoximone on PAP (pulmonary artery pressure) :
<b>Table (35)</b>	Showing mean, SD and P.value with peak effects of maxiumum dobutamine and enoximone on HR:
<b>Table (36)</b>	Showing Mean and SD of all hemodynamic parameter measured pre and post-dobutamine infusion, and their percentage change (%).
<b>Table (37)</b>	Showing mean and SD of all hemodynamic parameter measured pre and post-enoximone infusion,and their percentage change (%).

# List of Figures

- Figure (1):** Diagram of the circulation showing percentage of cardiac output distributed to different organ system (**Cardiovascular physiology. McGraw-Hill, 1981**)
- Figure (2):** A, a sarcomere as it appears under the electron microscope. B, is schematic of the location and interaction of actin and myosin.
- Figure (3):** The major molecules of the contractile system. Thin actin filament (**A**) interacts with the myosin head (**B**) when  $\text{Ca}^{++}$  ions arrive at troponin-C (**C**). The giant molecule Titin (**D**) provides structural support by linking myosin to the Z line. (**L.H.Opie. 1991**).
- Figure (4):** Phases of the action potential of cardiac muscle fiber and the corresponding changes in ionic conductance across the muscle membrane (**The Human CVS, Facts and Concepts. Raven Press. 1979**).
- Figure (5):** Calcium fluxes in the myocardium.
- Figure (6):** Signal systems involved in positive inotropic and lusitropic (enhanced relaxation) effects of beta-adrenergic stimulation.
- Figure (7):** Showing lung zones and their relation (From Ammetal ,1986).
- Figure (8):** The slope of the curve indicates the contractile status of the myocardium. (**Kaplan JA, 1993**).
- Figure (9):** Showing chemical structure of enoximone MDL 17,043 and its major hemodynamically active metabolite sulfoxide MDL 19,438 (Uretsky et al., 1986)
- Figure (10):** Influence of PDE inhibitors I, II and III on cyclic nucleotide metabolism (Kaplan et al., 1993).
- Figure (11):** Mechanism of action of PDE II inhibitors schematic representation of the sub cellular site of action of PDE III inhibitors (AC= adenylyl cyclase, GS= stimulatory guanine nucleotide binding protein RS= stimulatory; P protein kinase (**Kaplan et al., 1993**))
- Figure (12):** Showing effect of PDE inhibition in cardiac and vascular cells.

- Figure (13):** Showing the neurohormonal activation and its consequences in human heart failure
- Figure (14):** Swan-Ganz catheter
- Figure (15):** Normal pressure values and waveforms as a pulmonary catheter is advanced from the right atrium to a wedged position in a pulmonary artery (**Morgan et al., 1992**)
- Figure (16):** Showing the Echocardiographic machine used (Accuson Acuson phased array model XP128 10C)
- Figure (17):** Showing 2D-echocardiography of a dilated heart.  
A: Parasternal long axis, B: Aorta, C: Apical 4-chamber view.
- Figure (18):** Pressure at RA, B: Rt ventricular, C: Pul artery and D: PCWP.
- Figure (19):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on CI (Cardiac index).
- Figure (20):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on SVI (stroke volume index)
- Figure (21):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on LVSWI (left ventricular stroke work index).
- Figure (22):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on SVRI (systemic vascular resistance index)
- Figure (23):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on PVRI (pulmonary vascular resistance).
- Figure (24):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on PCWP (pulmonary capillary wedge pressure).
- Figure (25):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on RAP (right atrial pressure)
- Figure (26):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on MAP (mean arterial pressure)
- Figure (27):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on PAP (pulmonary artery pressure).
- Figure (28):** Comparative hemodynamic effects of dobutamine and enoximone at peak doses on HR (heart rate).



## **List of abbreviations**

CHF: Congestive heart failure  
CO: Cardiac output  
LAP: Left atrial pressure  
LVEDP: Left ventricular end-diastolic pressure  
LVEDV: Left ventricular end-diastolic volume  
MAP: Mean arterial pressure  
MPAP: mean pulmonary arterial pressure  
MVO<sub>2</sub>: Myocardial oxygen consumption  
NE: Norepinephrine  
PAC: pulmonary artery catheter  
PADP: pulmonary artery diastolic pressure  
PASP: pulmonary artery systolic pressure  
PCWP: pulmonary capillary wedge pressure  
PVR: Pulmonary vascular resistance  
RHC: right cardiac catheterization  
SR: Sarcoplasmic reticulum  
SV: Stroke volume  
SvO<sub>2</sub>: Mixed venous blood saturation  
SVR: Systemic vascular resistance